UCB SA (UCBJF) – What Are Researchers Thinking About This Stock?

Shares of UCB SA (OTCMKTS:UCBJF) have received a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company.

A number of research analysts have commented on UCBJF shares. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd.

UCB Price Performance

Shares of OTCMKTS UCBJF opened at $232.62 on Monday. UCB has a 12-month low of $219.60 and a 12-month high of $345.39. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average price of $251.62 and a 200 day moving average price of $279.03.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.